Our Pipeline
Psilocybin’s unique benefits
We seek to develop new, effective treatment options for patients without the adverse side effects of many alternatives.
Psilocybin’s potential to transform the treatment of several unique indicators has been researched by many well-respected academic institutions.
A closer look at patient needs.
Fibromyalgia
- Existing treatments have limited efficacy and significant side effects. Less than 10% of patients adhere to treatment after one year.
- Nearly 30% of fibromyalgia patients take opioids despite the lack of evidence of their efficacy and the risk of addiction and/or overdose.
- We estimate that there are approximately 4 million diagnosed cases of fibromyalgia in the United States.
Phantom Limb Pain
- There are nearly 2 million patients in the US living with the loss of a limb with more than 60% experiencing PLP at some point.
- PLP patients feel pain in limbs that no longer exist. As these pain signals are neurologically initiated, they are a prime target for treatment with psilocybin.
- Existing treatment methods such as general pain medication, mirror therapy and acupuncture have limited efficacy for many patients.
- We estimate that there are approximately 1 million diagnosed cases of PLP in the United States.
CRPS
- CRPS results from a misfiring of pain signals within the brain after an injury, surgery, stroke or heart attack.
- The brain becomes trained to signal pain at the time of injury and healing, but the pain signal persists even after the injury is fully healed and there is no local trauma.
- We estimate that there are nearly 100,000 diagnosed cases of CRPS in the United States.
We’re collaborating with top experts and research centers.
We’ve partnered with the Chronic Pain & Fatigue Research Center at the University of Michigan to advance our fibromyalgia studies—and we will be announcing partnerships for our clinical trials for phantom limb pain and complex regional pain syndrome soon.
A closer look at patient needs.
Binge Eating Disorder (BED)
- BED is characterized by recurring episodes of eating large quantities of food and feeling unable to stop.
- Nearly 30% of people seeking weight loss treatments show signs of BED.
- Up to 3.5% of females and 2.0% of males will develop BED at some point in their lives.
Hypothalamic Obesity
- Hypothalamic obesity, a rare disease, is caused by damage to the hypothalamus, which controls hunger.
- This damage is often caused by the surgical removal of a brain tumor.
- This condition can dominate patients’ day-to-day lives, and with no FDA-approved therapies available for the condition, patients have few options.
- This condition can dominate patients’ day-to-day lives, and with no FDA-approved therapies available for the condition, patients have few options.
We’re collaborating with top experts and research centers.
Tryp is collaborating with Jennifer Miller, M.D. from the University of Florida’s Division of Pediatric Endocrinology to evaluate the efficacy of our drug products. Dr. Miller is a world-renowned expert in overeating disorders such as binge eating and hypothalamic obesity
